Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

395
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
395
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

841
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
841
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

677
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
677
Depression: Overview01:18

Depression: Overview

399
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
399
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

231
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
231
Drug Therapy01:28

Drug Therapy

108
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
108

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge, attitudes, practices and ethics related to artificial intelligence among nursing students: a national cross-sectional survey in China.

BMC nursing·2026
Same author

Systematic Mental Health Care for Airline Pilots: Addressing Rare but Catastrophic Safety Outcomes.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same author

Dose Response Relationships of Loneliness and Insomnia With Subclinical Hikikomori Among College Students: A Multicentre Survey.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026
Same author

Associations between adverse childhood experiences and progression to incident psychiatric disorders in older adults: A 22-year cohort study.

Translational psychiatry·2026
Same author

The Prevalence of Frailty and Its Non-Linear Associations With Depressive Symptoms Among Cancer Survivors: A Multicenter Study With Network Analyses.

Psycho-oncology·2026
Same author

Inter-Relationships Between Depressive Symptoms And Sleep Problems Among Older Adults With Depression: Findings of a National Survey in the USA.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists·2026

Related Experiment Video

Updated: Sep 29, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

213

Antidepressants for COVID-19: A systematic review.

Wei Zheng1, He-Li Sun2, Hong Cai2

  • 1The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.

Journal of Affective Disorders
|March 27, 2022
PubMed
Summary

Emerging evidence suggests fluvoxamine may reduce mortality and hospitalization for COVID-19 patients. However, its safety profile requires further investigation, necessitating additional research on antidepressants for COVID-19 treatment.

Keywords:
AntidepressantsCOVID-19FluvoxamineSystematic review

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

747

Related Experiment Videos

Last Updated: Sep 29, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

213
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

747

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Coronavirus disease 2019 (COVID-19) poses significant global health challenges.
  • Antidepressants are being explored for potential therapeutic benefits in managing COVID-19.
  • Systematic reviews are crucial for evaluating the efficacy and safety of repurposed medications.

Purpose of the Study:

  • To systematically examine the efficacy and safety of antidepressants for treating COVID-19.
  • To synthesize evidence from various study designs regarding antidepressant use in COVID-19 patients.
  • To identify specific antidepressants with potential benefits and assess their safety profiles.

Main Methods:

  • A systematic literature search was conducted across multiple databases (PubMed, EMBASE, Cochrane Library, etc.).
  • Studies included retrospective analyses, randomized clinical trials (RCTs), and prospective cohort studies.
  • Data from a total of 92,947 patients with COVID-19 were analyzed.

Main Results:

  • Fluvoxamine demonstrated superior outcomes compared to placebo in RCTs, reducing clinical deterioration and hospitalization.
  • Antidepressants, including fluoxetine, showed potential in reducing mortality risk in retrospective studies.
  • Evidence suggests fluvoxamine may reduce mortality risk, though safety data from RCTs yielded inconsistent results without significant differences in dropout rates.

Conclusions:

  • Emerging evidence supports fluvoxamine's potential in reducing mortality and hospitalization in COVID-19 patients.
  • The safety of fluvoxamine for COVID-19 treatment remains inconclusive, requiring further rigorous evaluation.
  • Additional research is necessary to definitively establish the efficacy and safety of antidepressants for COVID-19 management.